April 18, 2025 – Harbin Metanotitia Technology Co., Ltd. ("Metanotitia") and Xiong’an Miaoxin Biotechnology Co., Ltd. ("Xiong’an Miaoxin") held a grand strategic cooperation signing ceremony at Zhongguancun Science Park in Xiong’an New Area. This collaboration signifies a deep integration of metabolomics and in vitro diagnostics between the two companies, jointly promoting the implementation of the “Healthy China” initiative and pioneering a new paradigm in precision health management and intelligent health screening services.

I. Background: Complementary Strengths, A Shared Future

• Since introducing metabolomics technology from the Max Planck Institute in 2018, Metanotitia has established three core technology platforms: high-throughput clinical metabolomics analysis, systems biology–driven AI, and translational medicine services. Based in the Harbin Metabolomics Precision Medicine Innovation Center and the Shenzhen Life & Health Laboratory, Metanotitia has built a full-chain capability from scientific research to commercialization, achieving significant outcomes in health management and disease diagnosis.

• Xiong’an Miaoxin focuses on five core modules: “health management, in vitro diagnostic reagents, testing services, artificial intelligence, and scientific and technological services.” The company has co-established a medical testing laboratory sharing platform with Zhongguancun Science Park and Xiong’an Group City Development Co., aiming to build an intelligent health management ecosystem integrating multi-omics data and AI technologies.

Through this partnership, Metanotitia will provide health management services powered by high-dimensional metabolomics data and AI-based interpretation, while Xiong’an Miaoxin will contribute its robust IVD reagent systems and testing service networks. This strong alliance is set to foster collaborative innovation across scenarios such as precision health management, chronic disease screening, and public health surveillance.

II. Signing Ceremony: Building a New Digital Health Ecosystem

At the ceremony, Dr. Liu Li, R&D Project Leader at Metanotitia, stated:
"This strategic collaboration marks an important step in our commercialization journey. We look forward to working closely with Xiong’an Miaoxin in technology translation and market deployment to co-create an integrated digital health ecosystem spanning data, algorithms, applications, and industries."

Mr. Xu Mengchao, General Manager of Xiong’an Miaoxin, remarked:
"Metanotitia’s leading position in metabolomics aligns perfectly with our strengths in intelligent health management platforms. Together, we aim to deliver more precise and accessible health services to users."

Following the ceremony, both teams toured Xiong’an Miaoxin’s Lifestyle Medicine Center, where they experienced a health assessment workflow powered by multi-omics data and wearable technologies. During the visit, Chief Engineer Peng Xing from Metanotitia's testing center and Dr. Zhang Lili, R&D lead at Xiong’an Miaoxin, engaged in deep technical discussions on sample collection QC and standardization of mass spectrometry data.

III. Key Collaboration Areas: Scenario-Driven, Application-Oriented

1. Precision Health Management
   • Co-develop personalized health assessment models based on metabolomics and AI algorithms to deliver full-chain services from metabolic age evaluation and disease risk prediction to intervention strategy recommendations.
2. Big Data and AI Empowerment
   • Integrate both parties’ data platforms to build a unified health big data center, leveraging multimodal data fusion and deep learning to continuously enhance diagnostics and management algorithms.
3. Ecosystem Innovation Collaboration
   • Capitalize on the favorable policy environment in Xiong’an New Area and the innovation resources of Zhongguancun to launch demonstration projects for national and international markets.

IV. Looking Ahead: Building a Healthier China Together

This strategic partnership marks the beginning of a deep collaboration between Metanotitia and Xiong’an Miaoxin. It is poised to become a new engine driving the clinical translation of metabolomics and the evolution of intelligent health management. Moving forward, both companies will increase investment in R&D, expand into diversified application scenarios, and contribute more Chinese innovation and solutions to enhance public health at scale.